Thea Pharma’s work to eliminate preservatives from latanoprost formulations has landed it an FDA nod in open-angle glaucoma and ocular hypertension, clearing the company to launch a differentiated rival to the incumbent eye drops.
Thea Pharma Announces FDA Approval of IYUZEH™ for the Reduction of Elevated Intraocular Pressure (IOP) in Patients with Open-angle Glaucoma or Ocular Hypertension